Loading…
Amwill Health Care (BSE 544353)₹43.50−1.14%Pharmaceuticals
In the Mar 2026 quarter (standalone), Amwill Health Care reported sales of ₹23.92 Cr, up 41.1% from Mar 2025, and net profit of ₹8.02 Cr, up 100.0% year on year. For the year to Mar 2026, sales were ₹42.85 Cr and net profit ₹11.03 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales | 22.93 | 16.95 | 20.94 | 23.92 |
| Expenses | 14.01 | 15.02 | 17.01 | 15.01 |
| Operating Profit | 8.97 | 2.99 | 3.99 | 8.97 |
| OPM % | 38.1% | 16.1% | 19.0% | 37.0% |
| Other Income | 0.00 | 0.99 | 0.99 | 1.99 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 8.96 | 2.99 | 4.99 | 9.97 |
| Tax % | 26.0% | −34.0% | 26.1% | 25.1% |
| Net Profit | 7.02 | 4.01 | 4.01 | 8.02 |
| EPS (Rs) | 4.17 | 2.09 | 1.92 | 3.76 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales | 16.96 | 25.93 | 27.94 | 41.91 | 36.90 | 42.85 |
| Expenses | 18.03 | 22.05 | 24.02 | 25.04 | 26.03 | 30.02 |
| Operating Profit | −0.99 | 3.99 | 3.98 | 16.96 | 11.97 | 12.96 |
| OPM % | −6.0% | 14.1% | 15.0% | 40.0% | 31.1% | 30.0% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 2.99 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 |
| Profit before tax | −0.99 | 2.99 | 3.99 | 16.94 | 11.95 | 14.95 |
| Tax % | −3.0% | 23.1% | 25.0% | 25.1% | 10.1% | 26.1% |
| Exceptional items | 0.00 | −0.06 | 0.00 | 0.01 | 0.00 | 0.00 |
| Net Profit | −1.01 | 3.01 | 3.01 | 12.03 | 11.04 | 11.03 |
| EPS (Rs) | −332.69 | 855.56 | 1,035.01 | 2,495.72 | 5.35 | 5.70 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 9.0% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0.02 | 0.02 | 0.02 | 0.04 | 19.93 | 19.93 |
| Reserves | −1.01 | 1.01 | 5.01 | 16.99 | 48.90 | 60.96 |
| Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 9.02 | 4.99 | 7.98 | 1.99 | 1.99 | 5.97 |
| Total Liabilities | 8.00 | 6.99 | 11.98 | 18.97 | 70.82 | 86.86 |
| Fixed Assets | 1.01 | 0.00 | 1.01 | 0.99 | 1.01 | 1.01 |
| CWIP | 0.00 | 0.00 | 0.00 | 1.01 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.99 |
| Other Assets | 6.99 | 5.99 | 11.97 | 17.97 | 69.81 | 82.86 |
| Inventories | 2.49 | 2.05 | 3.17 | 0.48 | 0.54 | 0.82 |
| Trade receivables | 4.42 | 0.89 | 1.24 | 12.99 | 16.76 | 20.94 |
| Cash & equivalents | 0.04 | 2.40 | 6.84 | 3.27 | 3.06 | 47.35 |
| Total Assets | 8.00 | 6.99 | 11.98 | 18.97 | 70.82 | 86.86 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from operating activity | 0.00 | 3.01 | 5.01 | −2.99 | 6.01 | 8.01 |
| Cash from investing activity | −1.01 | 0.00 | −1.01 | −1.01 | −46.09 | 6.01 |
| Cash from financing activity | 0.00 | 0.00 | 0.00 | 0.00 | 40.86 | 0.00 |
| Net cash flow | −0.99 | 2.99 | 2.99 | −3.99 | 0.99 | 13.94 |
| Capex | 0.79 | 0.10 | 0.30 | 0.88 | 0.71 | 0.57 |
| Free cash flow | −1.01 | 3.01 | 4.01 | −4.01 | 5.01 | 7.02 |
| CFO / OP % | −26.1% | 108.0% | 135.0% | 6.0% | 62.0% | 88.0% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor days | 92 | 11 | 15 | 113 | 162 | 176 |
| Inventory days | — | — | — | 66 | — | — |
| Days payable | — | — | — | 39 | — | — |
| Cash conversion cycle | 93 | 12 | 16 | 141 | 163 | 177 |
| Working capital days | −44 | −24 | −37 | 112 | 167 | 159 |
| ROCE % | — | 1,069.1% | 133.1% | 153.1% | 28.0% | 21.1% |
For the Mar 2026 quarter, Amwill Health Care reported sales of ₹23.92 Cr, up 41.1% year on year and net profit of ₹8.02 Cr, up 100.0% year on year. The operating margin was 37.0%.
Amwill Health Care's sales for the year to Mar 2026 were ₹42.85 Cr.
Net profit for the year to Mar 2026 was ₹11.03 Cr. Earnings per share over the same trailing period were ₹5.70.
Amwill Health Care reported borrowings of ₹0 Cr at Mar 2026, against cash and equivalents of ₹47.35 Cr.
Cash from operations was ₹8.01 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹7.02 Cr.